Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of Oral Lenalidomide and High Dose Melphalan Supported by Autologous Peripheral Blood Stem Cell Infusion for Patients With Multiple Myeloma

NCT01142232 is registered in ClinicalTrials.gov with Attaya Suvannasankha as lead sponsor.

NCT NCT01142232
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01142232 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of Oral Lenalidomide and High Dose Melphalan Supported by Autologous Peripheral Blood Stem Cell Infusion for Patients With Multiple Myeloma
Lead sponsor
Attaya Suvannasankha
Phase
Phase 1/2
Overall status
Completed
Start date
August 27, 2010
Completion date
May 18, 2019
Enrollment
60 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma